Parabilis Medicines Inc.
PBLS | NASDAQ
$27.18
-$1.14 (-4.03%)
Nov 2, 2026, 11:27 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Cash & Equivalents | 1.09B | 329.04M |
Short-Term Investments | 33.64M | n/a |
Long-Term Investments | n/a | n/a |
Other Long-Term Assets | 7.14M | 7.75M |
Receivables | n/a | n/a |
Inventory | n/a | n/a |
Other Current Assets | 4.7M | 3.03M |
Total Current Assets | 1.13B | 332.07M |
Property-Plant & Equipment | 42.73M | 44.36M |
Goodwill & Intangibles | n/a | n/a |
Total Long-Term Assets | 49.87M | 52.1M |
Total Assets | 1.18B | 384.17M |
Account Payables | 18.53M | 15.04M |
Deferred Revenue | 10.37M | n/a |
Short-Term Debt | 5.71M | 9.4M |
Other Current Liabilities | n/a | 7.61M |
Total Current Liabilities | 62.84M | 54.24M |
Long-Term Debt | n/a | n/a |
Other Long-Term Liabilities | n/a | 50M |
Total Long-Term Liabilities | 64.69M | 85.71M |
Total Liabilities | 127.53M | 139.95M |
Total Debt | 47.51M | 53.15M |
Book Value | 1.05B | 244.22M |
Book Value Per Share | 36.24 | 119.13 |
Common Stock | 12K | n/a |
Retained Earnings | -639.28M | -586.82M |
Comprehensive Income | -18K | n/a |
Shareholders Equity | 1.05B | 244.22M |
Total Investments | 33.64M | n/a |
Add to Watchlist
Select watchlists to add or remove PBLS